Forte Biosciences Inc
FBRX13.510USD
+0.300+2.27%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
165.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Forte Biosciences Inc Unternehmen
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Unternehmensinformationen
BörsenkürzelFBRX
Name des UnternehmensForte Biosciences Inc
IPO-datumApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 13
Addresse3060 Pegasus Park Drive
StadtDALLAS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl75247
Telefon13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
BörsenkürzelFBRX
IPO-datumApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
80.94K
+1.44%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.46K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fred Alger Management, LLC
13.02%
Federated Hermes Global Investment Management Corp.
11.89%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Andere
47.91%
Aktionäre
Aktionäre
Anteil
Fred Alger Management, LLC
13.02%
Federated Hermes Global Investment Management Corp.
11.89%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Andere
47.91%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
44.33%
Hedge Fund
25.35%
Private Equity
10.18%
Investment Advisor
5.53%
Corporation
3.95%
Individual Investor
1.01%
Research Firm
0.08%
Andere
9.58%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
80
7.19M
109.15%
+1.76M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
2023Q1
185
468.85K
56.07%
-1.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fred Alger Management, LLC
910.61K
13.83%
-223.34K
-19.70%
Mar 31, 2025
Janus Henderson Investors
920.00K
13.97%
+229.26K
+33.19%
Mar 31, 2025
OrbiMed Advisors, LLC
593.09K
9.01%
-6.91K
-1.15%
Mar 31, 2025
Tybourne Capital Management (HK) Limited
619.98K
9.42%
--
--
Mar 31, 2025
BVF Partners L.P.
594.28K
9.03%
--
--
Mar 31, 2025
Cable Car Capital LLC
219.60K
3.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
88.95K
1.35%
+62.56K
+237.01%
Mar 31, 2025
Ikarian Capital LLC
609.23K
9.25%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Datum
Art
Verhältnis
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
